CMS Open Payments · Program Year 2024
Lazarus 3D
Lazarus 3D reported $1,176.93 across General Payments, Research, and Ownership to 14 physicians and teaching hospitals across 14 transactions.
- $1.2K Below-median payer
- All-tracks total
- 14 Below-median volume
- Transactions
- 14 Below-median reach
- Recipients
- #1835
- of 1,925 companies
Lazarus 3D reported $1,176.93 across all CMS Open Payments tracks (General + Research + Ownership) to 14 physicians and teaching hospitals in Program Year 2024 - ranking #1835 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,176.93, averaging $84.07 per recipient.
How Lazarus 3D's $1.2K all-tracks total breaks down
Lazarus 3D's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer lazarus-3d Lazarus 3D
$1.2K · #1835/1,925 · 0.0% industry · PY2024
- TOT $1.2K
- RANK #1835
- SHARE 0.0%
- TXN 14
- RCP 14
- CAT 2
- GEN $1.2K
- TOP1 26.1%
- PY 2024
Volume peers
Nearest volume peer: GastroKlenz, Inc. DBA CloudCath ($1.2K)
Lazarus 3D sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Lazarus 3D
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Lazarus 3D, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $1.0K, accounting for 89.1% of this company's General Payments and 12 transactions.
General Payment Breakdown by Type
Lazarus 3D made 2 types of general payments. "Food and Beverage" is the largest category at $1.0K, 89.1% of General Payments.
How Lazarus 3D divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $1.0K | 12 | 89.1% |
| Gift | $128.49 | 2 | 10.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,013.78 (86.1%) of $1,176.93 in this company's General Payments records across 8 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Lazarus 3D
The five named recipients with the highest reported General Payments from this company
- 1
Rabin Gerrah
$306.93 across 4 reported transactions
- 2
Nicholas Tedesco
$243.83 across 3 reported transactions
- 3
William Harmon
$239.18 across 1 reported transactions
- 4
Layron Long
$124.30 across 2 reported transactions
- 5
Michael Ivan
$99.54 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Lazarus 3D ranks #1835 of 1,925 by total payments (bottom 5% by spend) but is notably more concentrated than that alone would suggest -- #793 of 1,838 by HHI (top 43% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- RMC Orthopedic & Surgical, Inc. : $13.5K total payments, HHI 1800
- NS Pharma, Inc. : $103.1K total payments, HHI 1796
- Avid Radiopharmaceuticals, Inc. : $8.1K total payments, HHI 1793
- Applied Medical Technology Inc : $176.9K total payments, HHI 1791
- Ignite Orthopedics, LLC : $705.4K total payments, HHI 1790
- BioPro, Inc. : $101.9K total payments, HHI 1788
- Lazarus 3D (this company) : $1.2K total payments, HHI 1788
- exocad America, Inc. : $54.9K total payments, HHI 1781
- Citieffe, Inc. : $145.4K total payments, HHI 1775
- Diagnostica Stago, Inc : $49.4K total payments, HHI 1775
- Cerus Corporation : $405.7K total payments, HHI 1771
- Brixton Biosciences, Inc. : $36.4K total payments, HHI 1756
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Lazarus 3D's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Lazarus 3D.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Lazarus 3D.
Showing 6 of 1,924 companies with CMS-reported payment data.
Dimension Inx Corp
Labcorp Holdings Inc.
Nsk America Corporation
Advanced Critical Devices, Inc.
Dash Medical Gloves LLC
Put this to use
Lazarus 3D ranks #1835 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Lazarus 3D. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.